Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Santaris, GlaxoSmithKline deal

Santaris and GSK partnered to discover, develop and commercialize RNA antagonists as antivirals. Santaris will be responsible for

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE